<DOC>
	<DOCNO>NCT01933152</DOCNO>
	<brief_summary>Retrospective , non-interventional , observational multi-center field study . Patients diagnose wet Age-related macular degeneration ( wAMD ) start treatment ranibizumab January 1 , 2009 December 31 , 2009 must consecutively screen , eligible , enrolled . Patients follow maximum December 31 , 2011 . Switch Anti vascular endothelial growth factor ( anti VEGF ) treatment document . For patient , demographic , medical history , administer treatment , result ocular visual assessment test ( available ) document .</brief_summary>
	<brief_title>Study Assess EffectiVeness exIsting Anti-vascular Endothelial groWth Factor ( Anti-VEGF ) Treatment Regimens Patients With Wet Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Diagnosis wet Agerelated Macular Degeneration Start antiVEGF therapy ranibizumab ( Lucentis ) January 1 , 2009 December 31 , 2009 Informed consent form sign Participation investigational study antiVEGF therapy ( start December 31 , 2011 ) involve treatment drug device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>wAMD</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>